IP Library Granted Patent US 7,341,869
Granted Patent B2
US 7,341,869 · App. 10/328,813 · Granted Mar 11, 2008

Compositions and methods for treating diabetes

Assignee: The University of Washington
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,341,869
App. No.
10/328,813
Granted
Mar 11, 2008
Kind
B2
Abstract

The present invention provides an isolated population of cells containing an expressible nucleic acid encoding proinsulin containing a proinsulin cleavage site and a glucose-regulated expressible nucleic acid encoding a protease capable of cleaving the proinsulin cleavage site to produce insulin. The invention also provides an isolated population of cells which further express a hexosamine synthetic pathway enzyme. The invention additionally provides vectors containing an expressible nucleic acid encoding proinsulin containing a proinsulin cleavage site and a glucose-regulated expressible nucleic acid encoding a protease capable of cleaving the proinsulin cleavage site to produce insulin. The invention further provides a method of treating or preventing diabetes by implanting into an individual cells coexpressing proinsulin containing a proinsulin cleavage site and a glucose-regulated protease capable of cleaving the proinsulin cleavage site to produce insulin.

Claims (10)

1. An isolated population of non-endocrine cells comprising an expressible nucleic acid encoding proinsulin containing a proinsulin cleavage site and a glucose-regulated expressible nucleic acid encoding an exogenous protease capable of cleaving said proinsulin cleavage site to produce insulin, wherein said cells express the hexosamine biosynthetic pathway enzyme glutamine:fructose-6-phosphate amidotransferase.

2. The isolated population of claim 1 , wherein said protease is furin.

3. The isolated population of claim 1 , wherein said glucose-regulated expressible nucleic acid further comprises a transforming growth factor-α(TGF-α) regulatory element.

4. The isolated population of claim 1 , wherein said proinsulin and said glucose-regulated protease are expressed from a single vector.

5. The isolated population of claim 4 , wherein said vector is a retroviral vector.

6. The isolated population of claim 4 , wherein said vector further comprises a selectable marker.

7. The isolated population of claim 1 , wherein said cells are smooth muscle cells.

8. The isolated population of claim 1 , wherein said proinsulin cleavage site further comprises the following tetrabasic sequence comprising the amino acids:

Arg-Xaa-Lys/Arg/Xaa-Arg (SEQ ID NO:7),

wherein Xaa comprises any amino acid.

Assignments (1)
CONFIRMATORY LICENSE Recorded Nov 14, 2016
From: UNIVERSITY OF WASHINGTON
To: NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR
Reel/Frame 040307/0034 →
Continuity (3)
Continuation 0918585200 · Nov 4, 1998
Provisional Application 6008766000 · Jun 2, 1998
Related Publication 20030113305A1 · Jun 19, 2003